Zhongren (David) Zhou, MD, PhD, FCAP


Associate Professor
Department of Pathology and Laboratory Medicine
University of Rochester Medical Center
601 Elmwood Avenue, Box 626
Rochester, NY 14642, USA

Biography

EDUCATIONAl QUALIFICATIONS

• (2/1994-07/1998) Postdoctoral Research Fellow, Biomedical Engineering Center Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA
• (8/1990-7/1993) PhD in Neurobiology, Shanghai Medical College, Fudan University, Shanghai, China
• (9/1986-8/1989) MS in Human Anatomy, Capital University of Medical Science, Beijing, China
• (8/1981-7/1986) MD, School of Medicine, Hebei United University, Tangshan, China

PROFESSIONAL EXPERIENCES

• (09/15-Present) Director, Biobank Core, Wilmot Cancer Center and Department of Pathology & Laboratory Medicine University of Rochester Medical Center; Rochester, NY
• (7/2013-Present) Interim Medical Director, Cytopathology Department of Pathology & Laboratory Medicine University of Rochester Medical Center; Rochester, NY

Research Interest

His research interest includes: Pathology and Laboratory Medicine.

Scientific Activities

HONORS AND AWARDS

• (1992) Guang-Hua Award for outstanding graduate student; Shangai Medical University
• (1992) Annual Science Festival Award for outstanding research work, Shanghai Medical University
• (2011) CAPA Award for the best research abstract

MEMBERSHIPS

• (1995-2002) Society of Neuroscience
• (2003- Present) ASCP (American Society for Clinical Pathologists)
• (2003- Present) CPA (College of American Pathologists)
• (2005- Present) CAPA (Chinese American Pathologists Association)
• (2005- Present) USCAP( United States & Canadian Academy of Pathology)
• (2010- Present) American Cytopathology Association
• (2013- Present) Western New York Society of Pathologists (Board member)
• (2013- Present) American Society of Cytopathology, Research and Current Concepts Committee (Board Member)
• (2014- Present) National Cancer Center, TCGA GI pathology committee

Publications

1. Sepesi B, Watson TJ, Zhou Z, et al . Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg. 2010; 210(4):418-27. doi: 10.1016/j.jamcollsurg.2010.01.003
2. Hu Y,Bandla S, Godfrey TE, et al. HER-2/Neu Over expression and Amplification in Esophageal Adenocarcinoma and High Grade Dysplasia. Modern Pathology. 2011 24: 899-907.
3. Feng W, Zhou Z, Peters JH Expression of insulin-like growth factor II mRNA-binding protein 3 in human esophageal adenocarcinoma and its precursor lesions. Arch Pathol Lab Med. 2011; 135(8): 1024–1031 doi: 10.5858/2009-0617-OAR2
4. Ismail A, Bandla S, Reveiller M, et al. Early G1 cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma. Clin Cancer Res. 2011; 17(13): 4513-4522. doi: 10.1158/1078-0432.CCR-11-0244
5. Dhingra S, Feng W, Brown RE, et al. Clinicopathologic significance of putative stem cell markers, CD44 and nestin, in gastric adenocarcinoma. Int J ClinExpPathol. 2011; 4(8): 733-741.
6. Liu X, Wu S, Xia Y, Li XE, Xia Y, Zhou ZD, Sun J.Wingless homolog Wnt 11 suppresses bacterial invasion and inflammation in intestinal epithelial cells. Am J PhysiolGastrointest Liver Physiol. 2011; 301(6): G992-G1003 doi: 10.1152/ajpgi.00080.2011.
7. Reveiller M, Ghatak S, Toia L,. Bile Exposure Inhibits Expression of Squamous Differentiation Genes in Human Esophageal Epithelial Cells Annals of Surgery . 2012; 255(6):1113-20. doi: 10.1097/SLA.0b013e3182512af9.
8. Choy B, S. Bandla, Y. Xia, D. Tan, T. Godfrey, J. Sun, Z Zhou, Clinicopathological characteristics of amplification and over expression of Bmi1 in esophageal adenocarcinoma and squamous cell carcinoma. BMC Gastroenterology. 2012; 12: 146. doi: 10.1186/1471-230X-12-146
9. Dulak A, P Stojanov, S Peng, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nature Genetics. 2013; 45: 478-486. doi: 10.1038/ng.2591
10. Li Zongtai, Xiaofang Zou, Liangxi Xie, et al. Prognostic Importance and Therapeutic Implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma. PLoS ONE. 8(11): e80665. doi: 10.1371/journal.pone.0080665
11. S. Bandla, JH Peters, D. Ruff, et al. Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without Goblet Cells. Annals Surgery online. 2014. doi: 10.1097/SLA.0000000000000424
12. Zhou Z, Bandla S, Ye J, et al. Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies. BMC Gastroenterology. 2014; 14: 78. doi: 10.1186/1471-230X-14-78
13. Zhang Y, Ren H, Ning Z, et al. Clinical impact of tumor-infiltrating inflammatory cells in primary small cell esophageal carcinoma. International Journal of Molecular Sciences 2014; 15: 9718-9734; doi: 10.3390/ijms15069718
14. 1Zhou Z, Xia Y, Bandla S, Zakharov V, Wu S, Peters J, Godfrey TE, Sun J. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant gender difference. Human Pathology. 2014; 45: 1744-1751. doi: 10.1016/j.humpath.2014.02.029
15. Lu R, Wu S, Zhang YG, et al. Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway. Oncogene. 2014; 3:e105. doi: doi: 10.1038/oncsis.2014.20.
16. Fox JKM, Peng S, Pusung M, et al. BassPre-existing alterations impact Trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. Journal of Clinical Research. 2014; 124(12): 5145-5158. doi: 10.1172/JCI75200
17. Huber AR, Tan D, Sun J, Dean D, Wu T, Zhou Z. High expression of carbonic anhydrase IX is significantly associated with glandular lesions in gastroesophageal junction and with tumorigenesis markers BMI1, MCM4 and MCM7. BMC Gastroenterology. 2015; 15: 80.doi: 10.1186/s12876-015-0310-6
18. Chuang KH, Whitney-Miller CL, Chu CY, et al. MicroRNA-494 is A Master Epigenetic Regulator of Multiple Invasion-Suppressor MicroRNAs via Targeting TET1 in Invasive Human HCC Tumors. Hepatology. 2015; 62(2): 466-480. doi: 10.1002/hep.27816
19. Costaldi ME, Lall A, Burack R, Zhou ZD. Using Flow Cytometry for the Diagnosis of Lung Neuroendocrine Carcinoma With Samples From Endobronchial Fine Needle Aspiration and Pleural Fluid. J.Interdiscipl.Histopathol. 2015; 3(1): 3-8. doi: 10.5455/jihp.20141201025029
20. Wu S, Zhang YG, Lu R, et al. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. Gut. 2015; 64(7):1082-1094. doi: 10.1136/gutjnl-2014-307436
21. Zhang YG, Wu S, Lu R, et al. Tight junction CLDN2 gene is a direct target of the vitamin D receptor. Scientific Report. 2015; 5: 10642. doi: 10.1038/srep10642.
22. Jiang M, Ku WY, Zhou Z, et al. BMP-driven NRF2 activation in esophageal basal cell differentiation and Eosinophilic Esophagitis. J. Clin. Inves. 2015; 125(4): 1557-1568. doi: 10.1172/JCI78850